Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Gains Phase III Candidate For Treatment Of Opioid Side Effects From Progenics

This article was originally published in The Pink Sheet Daily

Executive Summary

The $60 mil. deal gives Wyeth rights to three different dosage forms of methylnaltrexone for a range of opioid-induced conditions.
Advertisement

Related Content

First Roche, Then Bristol: Who’s Next?
First Roche, Then Bristol: Who’s Next?
Wyeth/Progenics File Methylnaltrexone Injection NDA For Opioid-Induced Constipation
Wyeth/Progenics File Methylnaltrexone Injection NDA For Opioid-Induced Constipation
Wyeth/Progenics Oral Methylnaltrexone Pushed Back A Year To Test New Formula
Wyeth/Progenics Oral Methylnaltrexone Pushed Back A Year To Test New Formula
Wyeth, Progenics To Develop Methylnaltrexone Franchise
Wyeth, Progenics To Develop Methylnaltrexone Franchise
Wyeth/Progenics Shoot For Early 2007 Methylnaltrexone NDA Submission
Wyeth/Progenics Shoot For Early 2007 Methylnaltrexone NDA Submission

Topics

Advertisement
UsernamePublicRestriction

Register

PS061450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel